I am conducting analysis on the treatment of cancer in secondary care and kindly request your help.
I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of April 2024 to the end of June 2024, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.
BREAST CANCER
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the
3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of medicine
|
|
Number patients treated
|
|
1.1 Abemaciclib (Verzenios)
|
|
|
|
1.2 Alpelisib (Piqray)
|
|
|
|
1.3 Fulvestrant (fulvestrant or Faslodex)
|
|
|
|
1.4 Palbociclib (Ibrance)
|
|
|
|
1.5 Ribociclib (Kisqali)
|
|
|
|
1.6 Capivasertib (Truqap)
|
|
|
Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period for which data are available?
Q3. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period for which data are available?
|
Treatment intent
|
|
Number patients treated
|
|
3.1 Curative
|
|
|
|
3.2 Palliative
|
|
|
|
3.3 Not known / stated
|
|
|
Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of combination or monotherapy
|
|
Number patients treated
|
|
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)
|
|
|
|
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)
|
|
|
|
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)
|
|
|
Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of April 2024 and end of June 2024?
|
Type of breast cancer
|
|
Number patients treated
|
|
5.1 all types of breast cancer
|
|
|
|
5.2 adjuvant treatment for early breast cancer
|
|
|
PROSTATE CANCER
Q6. How many patients were treated in total, regardless of diagnosis, with the following medicines in the
3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?
|
Name of medicine
|
|
Number patients treated
|
|
6.1 Abiraterone (Zytiga or generic abiraterone)
|
|
|
|
6.2 Apalutamide (Erleada)
|
|
|
|
6.3 Cabazitaxel (Jevtana or generic cabazitaxel)
|
|
|
|
6.4 Darolutamide (Nubeqa)
|
|
|
|
6.5 Enzalutamide (Xtandi)
|
|
|
Q7. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?
|
Name of medicine
|
|
Number patients treated
|
|
Docetaxel for prostate cancer
|
|
|
|
Olaparib (Lynparza) for prostate cancer
|
|
|
Q8. How many patients were treated with the following medicine combinations in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?
|
Name of medicine
|
|
Number patients treated
|
|
8.1 Abiraterone (Zytiga or abiraterone) + Androgen Deprivation Therapy
|
|
|
|
8.2 Apalutamide (Erleada) + Androgen Deprivation Therapy
|
|
|
|
8.3 Darolutamide (Nubeqa) + Docetaxel + ADT
|
|
|
|
8.4 Enzalutamide (Zytiga) + Androgen Deprivation Therapy
|
|
|
|
8.5 Olaparib (Lynparza) + Abiraterone
|
|
|
Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide
OVARIAN and ENDOMETRIAL CANCERS
Q9. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?
|
Name of medicine
|
|
Number patients treated
|
|
9.1 Dostarlimab (Jemperli)
|
|
|
|
9.2 Niraparib (Zejula)
|
|
|
|
9.3 Rucaparib (Rubraca)
|
|
|
|
9.4 Olaparib (Lynparza)
|
|
|
Q10. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?
|
Name of medicine
|
|
Number patients treated
|
|
10.1 Olaparib in total
|
|
|
|
10.2 Olaparib monotherapy
|
|
|
|
10.3 Olaparib + bevacizumab in combination
|
|
|
|
10.4 Bevacizumab total
|
|
|
|
10.5 Bevacizumab monotherapy
|
|
|
|
10.6 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin
|
|
|
